Semax Chemistry and ACTH Analog Mechanism
Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from ACTH(4-7)-PGP, an ACTH fragment with extended C-terminal pro-gly-pro dipeptide. The C-terminal Pro-Gly-Pro tripeptide extends the peptide's half-life (resistant to enzymatic degradation) and alters the receptor activation profile compared to native ACTH. Semax activates melanocortin receptors (primarily MC4R) in the brain rather than the adrenocortical ACTH receptor (MC2R), making Semax selective for neuronal effects without triggering cortisol production.
The heptapeptide structure (MW ~888 Da) is small enough to cross the blood-brain barrier (or penetrate brain tissue in ex vivo models) yet large enough to engage specific receptor selectivity. This selectivity is why Semax has been investigated as a neuroprotective research compound: BDNF induction without systemic glucocorticoid effects.
BDNF Upregulation Mechanism in Neural Cells
Semax treatment of primary cortical neurons, hippocampal neurons, and neural cell lines (SH-SY5Y, PC12) increases BDNF mRNA expression 1.5-3 fold as measured by qPCR. The mechanism involves MC4R activation → cAMP elevation → CREB (cAMP-responsive element binding protein) phosphorylation → CREB-mediated transactivation of the BDNF promoter (particularly BDNF exon I and IV promoters, which are CREB-responsive).
Downstream of BDNF synthesis, the peptide is released and can activate its cognate receptor TrkB (tropomyosin kinase B) on neurons in an autocrine or paracrine manner. TrkB activation leads to phosphorylation of downstream targets (Akt, ERK), supporting neuronal survival, synaptic plasticity, and mitochondrial homeostasis.
Neuroprotection Pathways and Cell Culture Models
Hypoxia models: Semax pre-treatment of cortical neurons exposed to hypoxia (1% O2) reduces neuronal apoptosis and maintains mitochondrial membrane potential. BDNF/TrkB signaling is hypothesized to support mitochondrial function during hypoxic stress.
Oxidative stress models: Semax pre-treatment of neurons exposed to H2O2 or rotenone (Complex I inhibitor) enhances survival and reduces ROS production. BDNF-mediated activation of Akt supports mitochondrial GSIS and glucose metabolism, improving ATP production under oxidative stress.
Excitotoxicity models: Semax protects neurons from NMDA or AMPA receptor overstimulation by enhancing BDNF-dependent survival signaling and reducing Ca2+ overload through CREB-dependent expression of calcium-buffering proteins.
Research Design: Cell Lines and Key Endpoints
Recommended cell models: Primary cortical or hippocampal neurons (highest BDNF responsiveness); SH-SY5Y neuroblastoma (human, widely available); PC12 cells (differentiated with NGF to enhance neuronal phenotype).
Key endpoints: (1) BDNF mRNA (qPCR); (2) BDNF protein (ELISA, Western blotting); (3) TrkB phosphorylation (pTrkB Tyr490 by Western); (4) Downstream kinases (pAkt Ser473, pERK1/2 Thr202/Tyr204); (5) Cell viability (MTS, LDH assay); (6) Mitochondrial function (membrane potential by TMRM, ATP content).
Concentration range: Published research uses Semax at 0.1-10 µM in cell culture. In vitro concentrations are substantially higher than likely CNS exposure in vivo (standard practice). Include a dose-response curve to characterize your specific cell type's response.
Semax is ACTH-based and primarily acts through melanocortin receptors (MC4R) → BDNF upregulation. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is tuftsin-based and acts through enkephalin-degrading enzyme inhibition and GABAergic pathways. The two have distinct mechanisms and non-overlapping targets, making them complementary tools for studying different neuroprotection pathways.
Frequently Asked Questions
FOR RESEARCH USE ONLY. Not for human or animal consumption.